Sat.Dec 04, 2021 - Fri.Dec 10, 2021

article thumbnail

A high-profile gene therapy biotech takes aim at Huntington's

Bio Pharma Dive

Passage Bio and the University of Pennsylvania's Gene Therapy Program said they have begun preclinical research aimed at simultaneously developing multiple approaches to treating Huntington's.

article thumbnail

Biogen: This train wreck was due

World of DTC Marketing

MY POINT : Success is always temporary. When all is said and one, the only thing you’ll have left is your character. Right now, I could make a great argument that Biogen’s character is trashed and that they are a company in dire need of authentic leadership. Massive layoffs could be headed to Biogen due to the disappointing rollout of its Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.

Drugs 231
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Is artificial intelligence the best tool for drug discovery?

Outsourcing Pharma

According to a leader from Cytoreason, AI isnât necessarily the best or only tool suited to discover new and novel therapiesâit might take a human touch.

Drugs 145
article thumbnail

Digital health firm Pear goes public, raising $175 million

pharmaphorum

Pear Therapeutics has completed its merger with blank cheque company Thimble Point Acquisition Corp, claiming a Nasdaq listing and raising $175 million in gross proceeds for the digital health specialist. Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

A serial biotech entrepreneur launches his next startup with high-dollar backing

Bio Pharma Dive

Founded and led by Gary Glick, Odyssey Therapeutics has raised $218 million in an initial fundraising round for its cancer and inflammatory disease drug research.

Drugs 352
article thumbnail

How much should I spend on an HCP website?

World of DTC Marketing

LEAD-IN- Recent data confirms that health care professionals are using the Internet more and spending less time with drug company reps. How much should you spend on an HCP portal, and how do you measure its success? One of the first questions I often get from potential clients is, “how much does a good HCP website cost?” There is no one answer to that question.

Branding 213

More Trending

article thumbnail

ACT for ALS Passes House while BrainStorm Prepares Moves Ahead with NurOwn

BioSpace

?A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.

131
131
article thumbnail

Fresh data show UniQure's hemophilia gene therapy appears to hold up

Bio Pharma Dive

The amount of blood clotting protein found in patients who received the medicine was nearly the same at six months and 18 months post-treatment, according to results disclosed Thursday.

article thumbnail

Do you have enough money to launch your drug?

World of DTC Marketing

LEAD IN: Pharma budgets are being scrutinized like never before, and DTC/HCP marketers must justify every dollar spent. I’m getting more requests to measure and justify spending for specific bucket tactics, and I believe once politicians get focused, they will scrutinize drug pricing and force negotiations with Medicare tightening internal expenditures even more.

Drugs 204
article thumbnail

Cambya Sugar Substitute Lets People Have Their Cake and Eat it Too

XTalks

B.T. Sweet, an Israeli food tech startup, recently unveiled a plant-based, one-to-one drop-in sugar substitute called Cambya. It can replace sugar in a multitude of applications in the chocolate and confectionary space, boasting the same levels of sweetness and body as real sugar. So, what is Cambya and what differentiates it from other sugar substitutes?

Branding 121
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

AI-based drug discovery firm BenevolentAI cuts SPAC deal

pharmaphorum

UK artificial intelligence specialist BenevolentAI has said it will float on the Amsterdam Euronext exchange in what is being touted as Europe’s largest ever special purpose acquisition company (SPAC) deal. BenevolentAI will merge with Odyssey Acquisition, a SPAC set up by investment bankers Michael and Yoel Zaoui that lists former Sanofi chief executive Olivier Brandicourt among its advisors – in a deal that will raise some €390 million in proceeds.

Drugs 119
article thumbnail

Latest Roche results show promise for new type of cancer immunotherapy

Bio Pharma Dive

Updated Phase 2 data suggested an experimental drug targeting the protein TIGIT could bolster the benefit of Roche's Tecentriq in certain people with advanced lung cancer.

Protein 317
article thumbnail

Valneva focuses its sights on the EU for its inactivated COVID-19 vaccine candidate

BioPharma Reporter

The European Medicines Agency (EMA) has started a rolling review of VLA2001, Valnevaâs COVID-19 vaccine candidate, with the company set to supply up to 60 million doses to the European Union.

article thumbnail

New Study: Fat Cells Are a Reservoir for COVID-19 Infection

BioSpace

Researchers published a study proving that SARS-CoV-2 infects human adipose or fat tissue to multiply and elicit an inflammatory response corresponding with severe COVID-19.

Research 120
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

CHMP recommend approval for Roche’s COVID-19 therapy

Pharma Times

According to clinical data, Roche’s new COVID-19 treatment Actemra/RoActemra lowered mortality risk in critically ill adult patients.

128
128
article thumbnail

Vaccine from Medicago, GSK protective against COVID-19 in large study

Bio Pharma Dive

The vaccine, which Medicago plans to soon submit to Canadian regulators, would be the first of its type, though supply appears likely to be limited.

article thumbnail

Flashfood App Helps Users Save on Groceries and Keep Food Out of Landfills

XTalks

Flashfood, a Toronto, Canada-based startup, is making it easier for consumers to save on groceries while simultaneously preventing unbought food from ending up in landfills. With skyrocketing grocery prices brought on by pandemic-driven inflation , Flashfood is offering a solution that is lighter on the consumers’ wallets and better for the planet. So, how does Flashfood work?

Branding 110
article thumbnail

Consumer health innovation – where passion and science meet

pharmaphorum

Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background in biochemistry and eye for identifying innovation trends, the future is bright at Johnson & Johnson Innovation. After making her way from early-stage drug development research to her current role, Heather got straight to work on creating sustainable collaborations that made life better for people and their families.

Allergies 105
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

WHO says vaccines should be effective against Omicron variant

Pharma Times

A senior official at the World Health Organisation (WHO) has said that Omicron is ‘highly unlikely’ to fully bypass vaccine protections.

article thumbnail

Martin Shkreli's former company to pay $40M in settlement over drug price hikes

Bio Pharma Dive

The payment resolves the government's claims against Vyera and Phoenixus for their efforts to block competition to Daraprim, the toxoplasmosis drug Shkreli famously raised the price of by 4,000%.

Drugs 294
article thumbnail

The Impossible Cheeseburger Claimed the Top Spot on Grubhub’s “Year in Food” Report

XTalks

Each year, food delivery platform Grubhub releases its “Year in Food” report, which analyzes millions of deliveries and highlights top orders. This year, the Impossible Cheeseburger made with plant-based ingredients beat out the spicy chicken sandwich for the top order position, increasing in popularity by 442 percent in 2021. Here are some more notable statistics from Grubhub’s “Year in Food” report.

Protein 105
article thumbnail

Plant-based COVID-19 vaccine candidate reports positive Phase 3 results

BioPharma Reporter

Medicago and GSKâs plant-based COVID-19 vaccine candidate has reported an overall efficacy rate of 71% in Phase 3 trials: with the final regulatory submission for the vaccine to be filed with Health Canada shortly.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

GPs in England to defer services to accelerate booster jab delivery

Pharma Times

GP practices can now postpone minor surgery and routine health checks for over-75s and new patients until 31 March 2022 to ensure booster jabs are rapidly and effectively delivered.

115
115
article thumbnail

AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug

Bio Pharma Dive

The alliance follows AstraZeneca's buyout of Alexion last year and puts the British drugmaker in competition with Alnylam, Bridgebio and several others.

Drugs 311
article thumbnail

Mind the gap: Are you delivering what HCPs value or what you want them to have?

pharmaphorum

Since the onset of the Covid-19 pandemic, life science companies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success (see graph 1). In the age of information overload, we all know that it is essential to add ‘value’ if we are to cut through the noise. And therein lies an issue. In a recent study by EPG Health, pharma respondents voted ‘providing real value’ the top challenge (of 23) related to digital Health Care Provider (HCP) engagement.

article thumbnail

Flashfood Grocery App + Mooless Animal-Free Whey Protein – Xtalks Food Podcast Ep. 40

XTalks

Would you take an extra step to browse through an app to save money on groceries and help cut down on food waste? In this episode of the Xtalks Food Podcast, Sydney talks about Flashfood, an app that allows users to shop for soon-to-expire groceries at a discount and divert food waste from landfills. The startup has partnered with around 1,200 grocery stores across the US and Canada and has plans to expand next year.

Protein 105
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

NICE publish final guidance recommending Aspaveli in adults with ultra-rare blood disorder

Pharma Times

The drug is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a marketing authorisation in the UK

Medicine 118
article thumbnail

Lilly deepens research ties in China with biotech deal

Bio Pharma Dive

The collaboration with Regor Therapeutics is another example of large pharma companies' interest in partnering with emerging biotechs from China.

article thumbnail

AbbVie prices first presbyopia drug Vuity at $80 per month

pharmaphorum

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects. The company told CBS it will charge around $80 for a 30-day supply of Vuity , a once-daily eyedrop formulation of muscarinic cholinergic agonist pilocarpine intended as an alternative to reading glasses, contact lenses or laser eye surgery.

Drugs 104
article thumbnail

Recursion and Roche Ink Multi-Billion Dollar AI Deal

BioSpace

Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.